Competing interests
P.
P. J. Mease has received grant/research support from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead Sciences, Janssen, Novartis, Pfizer Inc, Sun, and UCB; is a consultant for AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead Sciences, Janssen, Novartis, Pfizer Inc, Sun, and UCB; and has been on speakers’ bureaus for AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Genentech, Janssen, Novartis, Pfizer Inc, and UCB. A-M. Orbai has received grant/research support from AbbVie, Amgen, Celgene, Eli Lilly, Horizon, Janssen, and Novartis; and has received consulting fees from Bristol Myers Squibb, Janssen, Novartis, Pfizer Inc, Sanofi, and UCB. O. FitzGerald has received research grants from AbbVie, Bristol Myers Squibb, Eli Lilly, Novartis, and Pfizer Inc, has received consulting fees from Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, and Pfizer Inc, and has been on speakers’ bureaus for AbbVie, Janssen, and Pfizer Inc. M. Bedaiwi has been on speakers’ bureaus for AbbVie and Pfizer Inc. D. L. Fleishaker, R. Mundayat, and P. Young are employees and shareholders of Pfizer Inc. P. S. Helliwell is a consultant for Eli Lilly and has received fees for educational services from Janssen, Novartis, and Pfizer Inc.